Investors seem to be looking beyond the net loss numbers that Dr Reddy’s Laboratories reported in October-December (Q3) due to a one-off impairment charge. Overall revenues in Q3 rose 14% year-on-year with decent growth coming from the US and Indian markets. While the price erosion in the US still remains, Dr Reddy’s reported a steady 8% y-o-y revenue growth in the US market. Another positive this quarter has been domestic market growth where volumes are beginning to increase. Dr Reddy’s has reported decent growth in domestic categories.

Source: Mint January 27, 2020 10:30 UTC